Quantcast

Latest Beta amyloid Stories

2014-04-21 13:49:52

Compounds identified that stabilize retromer protein complex, which protects neurons from amyloid-beta A team of researchers from Columbia University Medical Center (CUMC), Weill Cornell Medical College, and Brandeis University has devised a wholly new approach to the treatment of Alzheimer's disease involving the so-called retromer protein complex. Retromer plays a vital role in neurons, steering amyloid precursor protein (APP) away from a region of the cell where APP is cleaved, creating...

2014-04-16 11:43:12

UC Irvine neurobiologists have found that genetically modified neural stem cells show positive results when transplanted into the brains of mice with the symptoms and pathology of Alzheimer's disease. The pre-clinical trial is published in the journal Stem Cells Research and Therapy, and the approach has been shown to work in two different mouse models. Alzheimer's disease, one of the most common forms of dementia, is associated with accumulation of the protein amyloid-beta in the brain in...

2014-04-14 14:20:45

Alzheimer's disease, the primary cause of dementia in the elderly, imposes a tremendous social and economic burden on modern society. In Japan, the burden of the disease in 2050 is estimated to be a half a trillion US dollars, a figure equivalent to the government's annual revenues. Unfortunately, it has proven very difficult to develop drugs capable of ameliorating the disease. After a tremendous burst of progress in the 1990s, the pace of discoveries has slowed. Dr. Saido believes that...

2014-03-31 08:29:05

MELBOURNE, Australia, March 31, 2014 /PRNewswire/ -- Prana Biotechnology (ASX:PBT/NASDAQ:PRAN) has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results. Prana's PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer's disease patients, as measured using PiB-PET Standardized Uptake Value...

2014-03-25 08:31:05

--Funds Will Advance Novel Approach for Treatment of Alzheimer's Disease and Other Diseases of Protein Aggregation-- CAMBRIDGE, Mass., March 25, 2014 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced the completion of a $17 million Series D financing from existing and new investors to advance the Company's lead candidate, NPT088, and potential next-generation compounds toward clinical trials. NPT088 has the potential to treat a wide range of neurodegenerative diseases,...

2014-03-20 12:33:23

BERLIN and BOSTON, March 20, 2014 /PRNewswire/ -- Piramal Imaging today announced that the U.S. Food and Drug Administration (FDA) has approved Neuraceq(TM). This approval comes only four weeks after receiving marketing authorization for Neuraceq(TM) from the European Commission. http://photos.prnewswire.com/prnvar/20140320/NE87281LOGO Neuraceq(TM) is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with...

2014-03-05 12:27:31

LEARN Project will Track Cognitive Change in a Comparison Group of Older Individuals, and Initiate the First Tau Imaging Study in a Longitudinal Prevention Trial CHICAGO, March 5, 2014 /PRNewswire-USNewswire/ -- The Alzheimer's Association today announced its largest ever research grant - $8 million over four years - to support the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) study as a companion study to the Anti-Amyloid Treatment in Asymptomatic Alzheimer's...

2014-03-05 10:35:00

Stem cells from patients offer model and drug-discovery platform for early-onset form of disease Harvard stem cell scientists have successfully converted skins cells from patients with early-onset Alzheimer's into the types of neurons that are affected by the disease, making it possible for the first time to study this leading form of dementia in living human cells. This may also make it possible to develop therapies far more quickly and accurately than before. The research, led by...

2014-02-20 08:31:52

- Milestone achieved for BI's initiation of Phase 1 study in beta-secretase (BACE) inhibitor program FORT WASHINGTON, Pa., Feb. 20, 2014 /PRNewswire/ -- Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and advancing novel, small molecule, best-in-class compounds, announced today that it has earned a $14 million milestone payment from Boehringer Ingelheim (BI) for BI's initiation of a Phase 1 clinical trial in the companies' beta-secretase...

Gordon Supercomputer Helps Guide New Drug Designs
2014-02-19 12:45:35

University of California, San Diego Single amyloid-beta monomers can pair up to form a variety of dimers that can aggregate into larger peptide rings that reside on cell membranes such as those pictured. This process has been implicated in the development of Alzheimer’s disease. This visualization shows the possible rings which have the most favorable energies of interactions with the membrane. The residues are colored white to represent apolar or hydrophobic areas, green for the polar...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related